News & Views
Diagnostic Clues Found for PAH
Mar 25 2019 Read 562 Times
Researchers at the University of Bradford have identified a biomarker that could be used to provide earlier diagnosis for Pulmonary arterial hypertension (PAH), a life limiting condition affecting around 6,500 people in the UK. Caused by a narrowing of the arteries supplying blood to the lungs and leading to possible heart failure, PAH can occur spontaneously at any age.
Led by Dr Talat Nasim, in Bradford’s School of Pharmacy and Medical Sciences and including researchers from the University of Cambridge (UK), Kings College London (UK), University of Dhaka (Bangladesh), Centre for Health Agricultural and Socio-economic Advancements (CHASA, Bangladesh) and Hacettepe University (Turkey), the study* builds on earlier research to investigate the genetic causes of PAH – in particular the mechanism of one faulty gene known as BMPR-II, which was first identified nearly two decades ago.
Dr Nasim explained: “We wanted to find out why the cells are not dying, but instead were building up inside the wall of the pulmonary arteries. To do this, we needed to identify and investigate the proteins that are influenced by this gene.”
The team discovered that the faulty BMPR-II gene affected one particular protein called Bcl-x. This, in turn, is responsible for making two different proteins, one of which increases cell apoptosis and the other one reduces it. These two work in balance in the body to regulate cell death. If BMPR-II is faulty, however, the protein for reducing cell apoptosis is increased – preventing cell death from occurring. “This protein can be used as a biomarker for accurately identifying PAH in patients,” said Dr Nasim. “This could help us diagnose PAH at an earlier stage, possibly leading to better treatment options for patients. We can also make other services available, such as genetic counselling, to help patients understand the disease and to identify those at risk of developing it.”
Dr Nasim’s team has filed a patent for the biomarker and is now investigating whether it could also be a target for new drugs. A number of promising compounds are currently being developed and tested.
*Published in Human Molecular Genetics
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Mass Spectrometry & Spectroscopy - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - Non-equivalent, Multivalen...
View all digital editions
Jan 25 2020 San Diego, CA, USA
Jan 27 2020 Dubai, UAE
Jan 29 2020 Tokyo, Japan
Feb 03 2020 Dubai, UAE
Feb 12 2020 Tokyo, Japan